PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35493482-0	2022	SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19).	azd1222	93-100	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	11-16	
35228013-5	2022	When AZD2816 is used as a booster dose in animals primed with a vaccine encoding the original spike protein (ChAdOx1 nCoV-19/ (AZD1222)), an increase in binding and neutralising antibodies against Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) is observed following each additional dose.	azd1222	127-134	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	94-99	
34189538-0	2021	T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.	azd1222	31-38	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	69-74	
34189538-3	2021	Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222.	azd1222	111-118	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	6-11	
34189538-3	2021	Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222.	azd1222	172-179	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	6-11	
34189538-6	2021	T-cell receptor (TCR) beta sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses.	azd1222	207-214	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	185-190	
34189538-8	2021	One Sentence Summary: Polyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222.	azd1222	145-152	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	104-109	
35214780-0	2022	Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2.	azd1222	121-128	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	18-23	
35214780-6	2022	In contrast, the heterologous prime-boost regimen using AZD1222 and BNT162b2 yielded the highest anti-spike IgG levels, which were 3-4.5 times more than the levels resulting from homologous AZD1222 and BNT162b2 vaccination, respectively.	azd1222	56-63	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	102-107	
35214780-6	2022	In contrast, the heterologous prime-boost regimen using AZD1222 and BNT162b2 yielded the highest anti-spike IgG levels, which were 3-4.5 times more than the levels resulting from homologous AZD1222 and BNT162b2 vaccination, respectively.	azd1222	190-197	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	102-107	
35042529-5	2022	Both vaccines induced spike protein-specific effector T cells which were dominated by type 1 helper T cell responses following AZD1222 vaccination.	azd1222	127-134	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	22-27